{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:52:39Z","timestamp":1776664359106,"version":"3.51.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Little is known about the optimal treatment for constipation in patients with schizophrenia or depression. Elobixibat is a laxative with a novel mechanism of action that inhibits the ileal bile acid transporter, acting as both an osmotic and a stimulant agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective, multicenter, postmarketing surveillance study to assess the safety and effectiveness of elobixibat for patients with chronic constipation in Japan (jRCT1080223950). The surveillance period was between June 2018 and May 2022. Patients were observed from the date of initial administration of elobixibat to 55 days thereafter (4-week treatment groups) or to 419 days thereafter (52-week treatment groups). Safety outcomes included adverse drug reactions (ADRs). Effectiveness outcomes included defecation frequency, Bristol Stool Form Scale (BSFS) scores, and constipation-related symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the safety analysis set, the 4-week treatment groups comprised 105 patients with schizophrenia and 129 with depression; the 52-week treatment groups included 43 patients with schizophrenia and 55 with depression. Approximately 85% to 95% of patients used antipsychotics, and 40% to 55% used anxiolytics or sedative-hypnotics. The proportions of patients who experienced ADRs were 4.76% in the 4-week treatment group and 2.33% in the 52-week treatment group of patients with schizophrenia, and 3.88% and 9.09% of patients with depression. Diarrhea was the most common ADR in each group. There were no serious ADRs. In the 4-week treatment groups, the mean defecation frequency per week at baseline was 3.3 among patients with schizophrenia and 3.0 among patients with depression, which increased to 5.3 and 4.9, respectively, at week 4. In the 52-week treatment groups, the mean defecation frequency per week at week 52 was higher than that at baseline. After treatment, the proportion of patients with an ideal BSFS score of 4 increased in all groups by week 2 and reached approximately 60% by week 52. All constipation-related symptoms also improved by week 2 in all groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elobixibat improved chronic constipation with no new safety signal identified in patients with schizophrenia or depression and with available follow-up in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:related-object>\n                      <jats:ext-link>https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT1080223950<\/jats:ext-link>\n                      , identifier jRCT1080223950.\n                    <\/jats:related-object>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1763059","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:45Z","timestamp":1776662625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan"],"prefix":"10.3389","volume":"17","author":[{"given":"Yoshiteru","family":"Takekita","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University","place":["Hirakata, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Umeyama","sequence":"additional","affiliation":[{"name":"Medical Department, EA Pharma Co., Ltd.","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie","family":"Iwaida","sequence":"additional","affiliation":[{"name":"Medical Department, EA Pharma Co., Ltd.","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Higashikawa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development Department, EA Pharma Co., Ltd.","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Shimada","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development Department, EA Pharma Co., Ltd.","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Atami Hospital, International University of Health and Welfare","place":["Atami, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17095","DOI":"10.1038\/nrdp.2017.95","article-title":"Chronic constipation","volume":"3","author":"Camilleri","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000502815","article-title":"Relationship between stool form and quality of life in patients with chronic constipation: an Internet questionnaire survey","volume":"102","author":"Ohkubo","year":"2021","journal-title":"Digestion"},{"key":"B3","unstructured":"Hany\n              M\n            \n            \n              Rizvi\n              A\n            \n          \n          Schizophrenia\n          \n          2024"},{"key":"B4","unstructured":"Chand\n              SP\n            \n            \n              Arif\n              H\n            \n          \n          Depression\n          \n          2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12888-022-04044-5","article-title":"Burden of schizophrenia among Japanese patients: a cross-sectional National Health and Wellness Survey","volume":"22","author":"Baba","year":"2022","journal-title":"BMC Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12894","article-title":"Prevalence of mental disorders and mental health service use in Japan","volume":"73","author":"Nishi","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"B7","unstructured":"Current status of health care and welfare measures for people with mental disorders"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1152435","article-title":"Association between constipation and major depression in adult Americans: evidence from NHANES 2005\u20132010","volume":"14","author":"Wang","year":"2023","journal-title":"Front Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e083668","DOI":"10.1136\/bmjopen-2023-083668","article-title":"Constipation among workers with depression\/anxiety: a retrospective study using a claims database and survey data in Japan","volume":"14","author":"Karasawa","year":"2024","journal-title":"BMJ Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4166\/kjg.2022.038","article-title":"Relationship between depression and constipation: results from a large cross-sectional study in adults","volume":"80","author":"Adibi","year":"2022","journal-title":"Korean J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12464","article-title":"Constipation-associated factors in outpatients with schizophrenia: a multicenter questionnaire survey","volume":"44","author":"Tazaki","year":"2024","journal-title":"Neuropsychopharmacol Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-024-02729-8","article-title":"Associations between constipation risk and lifestyle, medication use, and affective symptoms in patients with schizophrenia: a multicenter cross-sectional study","volume":"60","author":"Chiang","year":"2025","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9050581","article-title":"Association between anticholinergic burden and constipation: a systematic review","volume":"9","author":"Rodr\u00edguez-Ramallo","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-025-00551-3","article-title":"Genetic overlap between schizophrenia and constipation: insights from a genome-wide association study in a European population","volume":"24","author":"Luo","year":"2025","journal-title":"Ann Gen Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X14528269","article-title":"Elobixibat and its potential role in chronic idiopathic constipation","volume":"7","author":"Acosta","year":"2014","journal-title":"Therap Adv Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106644","article-title":"Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man","volume":"50","author":"Mekjian","year":"1971","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00194.2001","article-title":"The proximal colonic motor response to rectal mechanical and chemical stimulation","volume":"282","author":"Bampton","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B19","article-title":"Efficacy of elobixibat on defecation desire in patients with chronic constipation: a single center, retrospective, observational study","volume":"58","author":"Ishikawa","year":"2021","journal-title":"Med Consult New Rem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/20503121251321659","article-title":"A multicenter, postmarketing surveillance of elobixibat in patients with chronic constipation in Japan: a final analysis report","volume":"13","author":"Nakajima","year":"2025","journal-title":"SAGE Open Med"},{"key":"B22","first-page":"197","article-title":"The utilization of elobixibat against stimulant laxatives administration to psychiatric disordered patients with chronic constipation: a single-center, retrospective observational study","volume":"26","author":"Uno","year":"2023","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"B23","unstructured":"Japanese Society of Clinical Neuropsychopharmacology. Guideline for pharmacological therapy of schizophrenia 2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/npr2.12193","article-title":"Japanese society of neuropsychopharmacology: \u201cGuideline for pharmacological therapy of schizophrenia","volume":"41","year":"2021","journal-title":"Neuropsychopharmacol Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000540912","article-title":"Evidence-based clinical guidelines for chronic constipation 2023","volume":"106","author":"Ihara","year":"2025","journal-title":"Digestion"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1763059\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:47Z","timestamp":1776662627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1763059\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":25,"alternative-id":["10.3389\/fpsyt.2026.1763059"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1763059","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1763059"}}